$5370 | Single User
$5910 | Five User License
$7800 | Enterprise License

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors) - Global Opportunity Analysis and Industry Forecast, 2014-2022 [Report Updated: 23-02-2017]

Published by Allied Market Research: 23 Feb 2017 | 103456 | In Stock

Introduction

Human Immunodeficiency Virus (Hiv) Attacks The Body’s Immune System, Making The Host System Susceptible To Infection, And Thus Leading To Complete Damage. The Virus Attacks The Cd4 Cells, Which Help The Immune System Defend Infections. The Major Route Of Transmission Of Hiv Infection Is Through Unprotected Sex, Use Of Contaminated Needle, Breast Milk Of The Hiv Infected Mother, And Infected Blood.nnThe Global Hiv Drugs Market Was Valued At ,448 Million In 2015, And Is Estimated To Reach ,458 Million By 2022, Growing At A Cagr Of 3.7% During The Forecast Period From 2016 To 2022. The Major Factors That Boost The Growth Of The Market Include Increase In Prevalence Of Hiv Globally And Rise In Treatment & Diagnosis Rate. Moreover, Growth In Awareness About The Treatment Options & Care With The Various Initiatives And Education Campaigns Introduced By Government Agencies Across The Globe Plays An Important Role In The Growth Of Hiv Drugs Market. However, Stringent Government Regulations For The Approval And Commercialization Of Hiv Drugs Is Expected To Restrain The Growth Of The Hiv Drugs Market.nnThe Report Segments The Market Based On Medication Class And Geography. On The Basis Of Medication Class, The Market Is Divided Into Multi-Class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (Nrtis), Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis), Protease Inhibitors (Pis), Fusion Inhibitors (Fi), Entry Inhibitors, Hiv Integrase Stand Transfer Inhibitors. Based On Geography, The Market Is Analyzed Across North America, Europe, Asia-Pacific, And Lamea. The North American Region Accounted For Around Half Of The Share In The Overall Hiv Drug Market In 2015, And Is Expected To Maintain This Lead Throughout The Forecast Period. The Growth In The Hiv Drug Market In The Region Is Attributed To Well-Established Healthcare System, Higher Diagnosis & Treatment Rate In The Region, And Development And Increase In The Adoption Of Advanced Treatment Options From The Hiv Infected Population.nnKey Benefits for StakeholdersnnnnThe Study Provides An In-Depth Analysis Of The Hiv Drugs Market, With Current Trends And Future Estimations To Elucidate The Imminent Investment Pockets.nnIt Presents A Quantitative Analysis From 2014 To 2022 To Enable The Stakeholders To Capitalize On Prevailing Market Opportunities.nnExtensive Analysis Of The Hiv Drug Market, By Medication Class, Assists In The Effective Treatment Of Hiv/Aids.nnKey Players Are Profiled And Their Strategies Are Analyzed Thoroughly, Which Predicts The Competitive Outlook Of The Market.nnnHIV Drug Market Key SegmentsnnBy Medication ClassnnnnMulti-Class Combination DrugsnnnnnnAtriplannnComplerannnPrezcobix/PrezistannnStribildnnnTriumeqnnnnnnNucleoside Reverse Transcriptase Inhibitors (Nrtis)nnnnnCombivirnnnEmtrivannnEpivirnnnEpzicomnnnTrizivirnnnTruvadannnVireadnnnnnnNon-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis)nnnnnEdurantnnnIntelencennnRescriptornnnSustivannnViramune (Immediate Release)nnnnnnProtease Inhibitors (Pis)nnnnnAptivusnnnCrixivannnnKaletrannnLexivannnNorvirnnnReyataznnnViraceptnnnnnnFusion Inhibitors(Fi)nnnnnFuzeonnnnnnnEntry InhibitorsnnnnnSelzentrynnnnnnHiv Integrase Stand Transfer InhibitorsnnnnnIsentressnnnTivicaynnnnnnnBy GeographynnnnNorth AmericannEuropennAsia-PacificnnLameannnList Of Key Players Profiled in the ReportnnnnBoehringer Ingelheim International GmbhnnMerck & Co.nnBristol-Myers SquibbnnGilead Sciences Inc.nnViiv HealthcarennJohnson & JohnsonnnF. Hoffmann-La Roche Ltd.nnTeva Pharmaceutical Industries Ltd.nnAbbviennCipla LimitednnnList Of Other Players in the Value Chainnnnn(These Players Are Not Profiled In The Report. The Same Will Be Included On Request)nnDaiichi SankyonnEmcurennHetero DrugsnnMylannnAstrazenecan

Table of Contents
for HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors) - Global Opportunity Analysis and Industry Forecast, 2014-2022 [Report Updated: 23-02-2017]

  • CHAPTER 1 INTRODUCTION

    1.1. REPORT DESCRIPTION
    1.2. KEY BENEFITS
    1.3. KEY MARKET SEGMENTS
    1.4. RESEARCH METHODOLOGY

    1.4.1. Secondary research
    1.4.2. Primary research
    1.4.3. Analyst tools and models

    CHAPTER 2 EXECUTIVE SUMMARY

    2.1. CXO PERSPECTIVE

    CHAPTER 3 MARKET OVERVIEW

    3.1. MARKET DEFINITION AND SCOPE
    3.2. KEY FINDINGS

    3.2.1. Top investment pockets
    3.2.2. Top winning strategies

    3.3. MARKET SHARE ANALYSIS
    3.4. PRODUCT PIPELINE ANALYSIS
    3.5. MARKET DYNAMICS

    CHAPTER 4 HIV DRUGS MARKET, BY MEDICATION CLASS

    4.1. OVERVIEW
    4.2. MULTI-CLASS COMBINATION DRUGS

    4.2.1. Key market trends
    4.2.2. Key growth factors and opportunities
    4.2.3. Market size and forecast
    4.2.4. Atripla: market size and forecast
    4.2.5. Complera: market size and forecast
    4.2.6. Prezista: market size and forecast
    4.2.7. Stribild: market size and forecast
    4.2.8. Triumeq: market size and forecast

    4.3. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)

    4.3.1. Key market trends
    4.3.2. Key growth factors and opportunities
    4.3.3. Market size and forecast
    4.3.4. Combivir: market size and forecast
    4.3.5. Emtriva: market size and forecast
    4.3.6. Epivir: market size and forecast
    4.3.7. Epzicom: market size and forecast
    4.3.8. Trizivir: market size and forecast
    4.3.9. Truvada: market size and forecast
    4.3.10. Viread: market size and forecast

    4.4. NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)

    4.4.1. Key market trends
    4.4.2. Key growth factors and opportunities
    4.4.3. Market size and forecast
    4.4.4. Edurant: market size and forecast
    4.4.5. Rescriptor: market size and forecast
    4.4.6. Sustiva: market size and forecast
    4.4.7. Viramune: market size and forecast

    4.5. PROTEASE INHIBITORS (PIS)

    4.5.1. Key market trends
    4.5.2. Key growth factors and opportunities
    4.5.3. Market size and forecast
    4.5.4. Aptivus: market size and forecast
    4.5.5. Crixivan: market size and forecast
    4.5.6. Kaletra: market size and forecast
    4.5.7. Lexiva: market size and forecast
    4.5.8. Norvir: market size and forecast
    4.5.9. Reyataz: market size and forecast
    4.5.10. Viracept: market size and forecast

    4.6. FUSION INHIBITORS

    4.6.1. Key market trends
    4.6.2. Key growth factors and opportunities
    4.6.3. Market size and forecast
    4.6.4. Fuzeon: market size and forecast

    4.7. ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST

    4.7.1. Key market trends
    4.7.2. Key growth factors and opportunities
    4.7.3. Market size and forecast
    4.7.4. Selzentry: market size and forecast

    4.8. HIV INTEGRASE STRAND TRANSFER INHIBITORS

    4.8.1. Key market trends
    4.8.2. Key growth factors and opportunities
    4.8.3. Market size and forecast
    4.8.4. Isentress: market size and forecast
    4.8.5. Tivicay: market size and forecast

    CHAPTER 5 HIV DRUGS MARKET, BY GEOGRAPHY

    5.1. OVERVIEW

    5.1.1. Market size and forecast

    5.2. NORTH AMERICA

    5.2.1. Key market trends
    5.2.2. Key growth factors and opportunities
    5.2.3. Market size and forecast

    5.3. EUROPE

    5.3.1. Key market trends
    5.3.2. Key growth factors and opportunities
    5.3.3. Market size and forecast

    5.4. ASIA-PACIFIC

    5.4.1. Key market trends
    5.4.2. Key growth factors and opportunities
    5.4.3. Market size and forecast

    5.5. LAMEA

    5.5.1. Key market trends
    5.5.2. Key growth factors and opportunities
    5.5.3. Market size and forecast

    CHAPTER 6 COMPANY PROFILES

    6.1. BOEHRINGER INGELHEIM INTERNATIONAL GMBH

    6.1.1. Overview
    6.1.2. Operating business segments
    6.1.3. Business performance
    6.1.4. Key strategic moves & developments

    6.2. MERCK & CO., INC.

    6.2.1. Overview
    6.2.2. Operating business segments
    6.2.3. Business performance
    6.2.4. Key strategic moves & developments

    6.3. BRISTOL-MYERS SQUIBB

    6.3.1. Overview
    6.3.2. Operating business segments
    6.3.3. Business performance
    6.3.4. Key strategic moves & developments

    6.4. GILEAD SCIENCES, INC.

    6.4.1. Overview
    6.4.2. Operating business segments
    6.4.3. Business performance
    6.4.4. Key strategic moves & developments

    6.5. VIIV HEALTHCARE

    6.5.1. Overview
    6.5.2. Operating business segments
    6.5.3. Business performance
    6.5.4. Key strategic moves & developments

    6.6. JOHNSON & JOHNSON

    6.6.1. Overview
    6.6.2. Operating business segments
    6.6.3. Business performance
    6.6.4. Key Strategic Moves & Developments

    6.7. F. HOFFMANN-LA ROCHE LTD

    6.7.1. Overview
    6.7.2. Operating business segments
    6.7.3. Business performance
    6.7.4. Key Strategic Moves & Developments

    6.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.

    6.8.1. Overview
    6.8.2. Operating business segments
    6.8.3. Business performance
    6.8.4. Key Strategic Moves & Developments

    6.9. ABBVIE

    6.9.1. Overview
    6.9.2. Operating business segments
    6.9.3. Business performance
    6.9.4. Key strategic moves & developments

    6.10. CIPLA

    6.10.1. Overview
    6.10.2. Operating business segments
    6.10.3. Business performance
    6.10.4. Key Strategic Moves & Developments

    LIST OF OTHER PLAYERS IN THE VALUE CHAIN

    (These players are not profiled in the report. The same will be included on request)



    Daiichi Sankyo

    Emcure

    Hetero Drugs

    Mylan

    AstraZeneca


    LIST OF TABLES

    TABLE 1. HIV PRODUCT PIPELINE: ANTIVIRALS
    TABLE 2. HIV PRODUCT PIPELINE: CELL THERAPY/GENE THERAPY
    TABLE 3. HIV PRODUCT PIPELINE: IMMUNOMODULATORS
    TABLE 4. GLOBAL HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
    TABLE 5. GLOBAL MULTI-CLASS COMBINATION DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
    TABLE 6. GLOBAL MULTI-CLASS COMBINATION DRUGS MARKET, BY BRAND, 2014-2022 ($MILLION)
    TABLE 7. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
    TABLE 8. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET, BY BRAND TYPE, 2014-2022 ($MILLION)
    TABLE 9. GLOBAL NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
    TABLE 10. GLOBAL NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) MARKET, BY BRAND TYPE, 2014-2022 ($MILLION)
    TABLE 11. GLOBAL PROTEASE INHIBITORS (PIS) MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
    TABLE 12. GLOBAL PROTEASE INHIBITORS (PIS) MARKET, BY BRAND TYPE, 2014-2022 ($MILLION)
    TABLE 13. GLOBAL FUSION INHIBITORS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
    TABLE 14. GLOBAL ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
    TABLE 15. GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
    TABLE 16. GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS MARKET, BY BRAND TYPE, 2014-2022 ($MILLION)
    TABLE 17. GLOBAL HIV DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
    TABLE 18. NORTH AMERICA: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
    TABLE 19. EUROPE: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
    TABLE 20. AISA-PACIFIC: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
    TABLE 21. LAMEA: HIV DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
    TABLE 22. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
    TABLE 23. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
    TABLE 24. MERCK: COMPANY SNAPSHOT
    TABLE 25. MERCK: OPERATING SEGMENTS
    TABLE 26. BMS: COMPANY SNAPSHOT
    TABLE 27. GILEAD: COMPANY SNAPSHOT
    TABLE 28. VIIV HEALTHCARE: COMPANY SNAPSHOT
    TABLE 29. JOHNSON & JOHNSON: COMPANY SNAPSHOT
    TABLE 30. JOHNSON & JOHNSON: OPERATING BUSINESS SEGMENTS
    TABLE 31. ROCHE: COMPANY SNAPSHOT
    TABLE 32. ROCHE: OPERATING SEGMENTS
    TABLE 33. TEVA PHARMACEUTICAL: COMPANY SNAPSHOT
    TABLE 34. TEVA: OPERATING SEGMENTS
    TABLE 35. ABBVIE: COMPANY SNAPSHOT
    TABLE 36. CIPLA LIMITED: COMPANY SNAPSHOT

    LIST OF FIGURES

    FIGURE 1. HIV DRUGS: MARKET SEGMENTATION
    FIGURE 2. TOP INVESTMENT POCKETS
    FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2014-2016
    FIGURE 4. HIV DRUGS MARKET SHARE ANALYSIS, 2015
    FIGURE 5. PRODUCT PIPELINE ANALYSIS
    FIGURE 6. GLOBAL ATRIPLA MARKET, 2014-2022 ($MILLION)
    FIGURE 7. GLOBAL COMPLERA MARKET, 2014-2022 ($MILLION)
    FIGURE 8. GLOBAL PREZISTA MARKET, 2014-2022 ($MILLION)
    FIGURE 9. GLOBAL STRIBILD MARKET, 2014-2022 ($MILLION)
    FIGURE 10. GLOBAL TRIUMEQ MARKET, 2014-2022 ($MILLION)
    FIGURE 11. GLOBAL COMBIVIR MARKET, 2014-2022 ($MILLION)
    FIGURE 12. GLOBAL EMTRIVA MARKET, 2014-2022 ($MILLION)
    FIGURE 13. GLOBAL EPIVIR MARKET, 2014-2022 ($MILLION)
    FIGURE 14. GLOBAL EPZICOM MARKET, 2014-2022 ($MILLION)
    FIGURE 15. GLOBAL TRIZIVIR MARKET, 2014-2022 ($MILLION)
    FIGURE 16. GLOBAL TRUVADA MARKET, 2014-2022 ($MILLION)
    FIGURE 17. GLOBAL VIREAD MARKET, 2014-2022 ($MILLION)
    FIGURE 18. GLOBAL EDURANT MARKET, 2014-2022 ($MILLION)
    FIGURE 19. GLOBAL INTELENCE MARKET, 2014-2022 ($MILLION)
    FIGURE 20. GLOBAL RESCRIPTOR MARKET, 2014-2022 ($MILLION)
    FIGURE 21. GLOBAL SUSTIVA MARKET, 2014-2022 ($MILLION)
    FIGURE 22. GLOBAL VIRAMUNE MARKET, 2014-2022 ($MILLION)
    FIGURE 23. GLOBAL APTIVUS MARKET, 2014-2022 ($MILLION)
    FIGURE 24. GLOBAL CRIXIVAN MARKET, 2014-2022 ($MILLION)
    FIGURE 25. GLOBAL KALETRA MARKET, 2014-2022 ($MILLION)
    FIGURE 26. GLOBAL LEXIVA MARKET, 2014-2022 ($MILLION)
    FIGURE 27. GLOBAL NORVIR MARKET, 2014-2022 ($MILLION)
    FIGURE 28. GLOBAL REYATAZ MARKET, 2014-2022 ($MILLION)
    FIGURE 29. GLOBAL VIRACEPT MARKET, 2014-2022 ($MILLION)
    FIGURE 30. GLOBAL FUZEON MARKET, 2014-2022 ($MILLION)
    FIGURE 31. GLOBAL SELZENTRY MARKET, 2014-2022 ($MILLION)
    FIGURE 32. GLOBAL ISENTRESS MARKET, 2014-2022 ($MILLION)
    FIGURE 33. GLOBAL TIVICAY MARKET, 2014-2022 ($MILLION)
    FIGURE 34. BOEHRINGER INGELHEIM: REVENUE, 2013-2015 ($MILLION)
    FIGURE 35. MERCK: REVENUE, 2013-2015 ($MILLION)
    FIGURE 36. BMS: REVENUE, 2013-2015 ($MILLION)
    FIGURE 37. GILEAD: REVENUE, 2013-2015 ($MILLION)
    FIGURE 38. JOHNSON & JOHNSON: REVENUE, 2013-2015, ($MILLION)
    FIGURE 39. ROCHE: REVENUE, 2013-2015, ($MILLION)
    FIGURE 40. TEVA: REVENUE, 2013-2015, ($MILLION)
    FIGURE 41. ABBVIE: REVENUE, 2013-2015 ($MILLION)
    FIGURE 42. CIPLA: REVENUE, 2013-2015 ($MILLION)

Additional Details

Publisher

Allied Market Research

Publisher Information

Reference

103456 | LI 171867

Number of Pages

163

Report Format

PDF

Allied Market Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Orphan Drug Commercial Models: Sustaining the rare disease business
IntroductionChoosing the right commercial model for orphan drug successThe societal and commercial a...
01 May 2016 by FirstWord Pharma USD $695 More Info
Pay-for-Performance and Drug Pricing: Impact and Response of Pharma [2016]
IntroductionThe pay for performance agenda gathers pace as US payers rebel the cost of drugs.Pharma ...
01 Mar 2016 by FirstWord Pharma USD $695 More Info
Innovations in Drug Pricing and Reimbursement (2016)
IntroductionIs the drug pricing bubble about to burst?Drug costs are becoming unaffordable and draco...
01 Feb 2016 by FirstWord Pharma USD $2,195 More Info
Drug Delivery - Innovations, trends, and their impact on pharma
IntroductionWhy you need Drug Delivery - Innovations, trends, and their impact on pharmaRevolutionar...
01 Nov 2015 by FirstWord Pharma USD $2,195 More Info
Physician Views: Which companies excel in diabetes drug marketing and why?
Scope With both the insulin and non-insulin segments of the diabetes market expected to become more ...
01 May 2015 by FirstWord Pharma USD $695 More Info
Trends and Innovations in Drug Pricing
IntroductionFirstWord’s Trends and Innovations in Drug Pricing report dissects international trends ...
01 Jan 2015 by FirstWord Pharma USD $695 More Info
Orphan Drug Market Access: Payer Insights on the Present and Future
IntroductionOrphan Drug Market Access: Payer Insights on the Present and Future is a report that exa...
14 Oct 2014 by FirstWord Pharma USD $695 More Info
Physician Views: With drug developers on the brink of Phase III for NASH, how large is the actual market opportunity?
Scope While no drugs are approved for non-alcoholic steatohepatitis (NASH), at least eight agents ha...
04 Aug 2014 by FirstWord Pharma USD $695 More Info
Physician Views: As Tecfidera approaches a critical juncture in Europe, how are neurologist perceptions towards Biogen Idec's MS drug shaping up?
ScopeSales of Biogen Idec’s multiple sclerosis therapy Tecfidera may continue to exceed initial expe...
01 Nov 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
01 Jun 2013 by FirstWord Pharma USD $695 More Info

This report is published by Allied Market Research

Download Free Report Summary PDF

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FI), entry inhibitors, and HIV integrase stand transfer inhibitors) - Global Opportunity Analysis and Industry Forecast, 2014-2022 [Report Updated: 23-02-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data